RAC · ASX

Race Oncology Ltd. (ASX:RAC)

AU$1.24

 0.01 (0.816%)
ASX:Live
09/05/2025 12:20:25 PM
HALO Ords HALO Consensus Value GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

RAC Overview

RAC Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About RAC

Website

Race Oncology Ltd.

Telephone

61.2.8051.3043

Address

Level 36, Gateway 1 Macquarie Place Sydney, New South Wales (NSW) 2000

Description

Race Oncology Ltd. is a clinical stage biotechnology company, which engages in the discovery and development of a novel approach to cancer treatment and cardio protection. The firm is involved in developing Bisantrene, a small molecule anthracene chemotherapeutic, to address the unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer and acute myeloid leukemia. It is also investigating the impact Bisantrene and new molecules have on the m6A RNA pathway. The company was founded on February 15, 2011 and is headquartered in Sydney, Australia.

RAC Price Chart

Key Stats

Market Cap

AU$202.39M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.92 - 2.09

Trade Value (12mth)

AU$47,284.00

1 week

1.24%

1 month

22.5%

YTD

-10.58%

1 year

-6.84%

All time high

4.23

Key Fundamentals

EPS 3 yr Growth

73.60%

EBITDA Margin

N/A

Operating Cashflow

-$10m

Free Cash Flow Return

-43.60%

ROIC

-63.10%

Interest Coverage

N/A

Quick Ratio

9.30

Other Data

Shares on Issue (Fully Dilluted)

193m

HALO Sector

Healthcare

Next Company Report Date

22-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.02

RAC Announcements

Latest Announcements

Date Announcements

07 May 25

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

06 May 25

Notification of cessation of securities - RAC

×

Notification of cessation of securities - RAC

05 May 25

Race Announces Key Senior Clinical Team Appointments

×

Race Announces Key Senior Clinical Team Appointments

01 May 25

First Patient Dosed Safely in RC220 Phase 1 Trial

×

First Patient Dosed Safely in RC220 Phase 1 Trial

23 April 25

March 2025 Quarterly Activity Report and Appendix 4C

×

March 2025 Quarterly Activity Report and Appendix 4C

22 April 25

Enrolment Opened at Second Site for RC220 Phase 1 Trial

×

Enrolment Opened at Second Site for RC220 Phase 1 Trial

03 April 25

RC220 Phase 1 Trial Opens for Patient Enrolment

×

RC220 Phase 1 Trial Opens for Patient Enrolment

31 March 25

Ethics approval for RC220 Trial at Gosford Wyong Hospitals

×

Ethics approval for RC220 Trial at Gosford Wyong Hospitals

27 March 25

Race Initiates First AU Site for Phase 1 Solid Tumour Trial

×

Race Initiates First AU Site for Phase 1 Solid Tumour Trial

17 March 25

Race Investor Presentation

×

Race Investor Presentation

14 March 25

Ethics approval received for RC220 Phase 1 Trial

×

Ethics approval received for RC220 Phase 1 Trial

14 March 25

Race Online Investor Briefing Invitation

×

Race Online Investor Briefing Invitation

07 March 25

S&P DJI Announces March 2025 Quarterly Rebalance

×

S&P DJI Announces March 2025 Quarterly Rebalance

05 March 25

Race Signs Contract for Phase 1 Trial of RC220

×

Race Signs Contract for Phase 1 Trial of RC220

25 February 25

Appendix 4D & Half-Year Financial Statements

×

Appendix 4D & Half-Year Financial Statements

04 February 25

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

31 January 25

Quarterly Activity Report and Appendix 4C

×

Quarterly Activity Report and Appendix 4C

16 January 25

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

02 January 25

Appendix 3X - Dr Megan Baldwin

×

Appendix 3X - Dr Megan Baldwin

18 December 24

Race Strengthens Board

×

Race Strengthens Board

17 December 24

Race Receives $5.25m RD Tax Refund for Financial Year 2024

×

Race Receives $5.25m RD Tax Refund for Financial Year 2024

05 December 24

Race Submits Human Ethics for RC220 Phase 1 Trial

×

Race Submits Human Ethics for RC220 Phase 1 Trial

28 November 24

Race 2024 Annual General Meeting Video Release

×

Race 2024 Annual General Meeting Video Release

26 November 24

Notification regarding unquoted securities - RAC

×

Notification regarding unquoted securities - RAC

26 November 24

Appendix 3Y - Dr Serge Scrofani

×

Appendix 3Y - Dr Serge Scrofani

RAC Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.07 -0.06 -0.08 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.07 -0.06 -0.08 Lock Lock Lock
     Growth % Lock Lock Lock Lock -51.0 15.6 -36.1 Lock Lock Lock
     PE X Lock Lock Lock Lock 22.0 N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock 24.3 N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.05 -0.06 -0.07 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.04 -0.07 -0.06 Lock Lock Lock
     Growth % Lock Lock Lock Lock -85.5 -12.3 -29.2 Lock Lock Lock
     Yield % Lock Lock Lock Lock -2.1 -5.4 -3.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.0 N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.23 0.16 0.11 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.21 0.14 0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock 192.8 -33.1 -33.7 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 153 161 165 Lock Lock Lock
Basic m Lock Lock Lock Lock 153 161 165 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 11 13 18 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -11 -13 -18 Lock Lock Lock
     Growth % Lock Lock Lock Lock -80.9 -13.4 -38.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -11 -13 -18 Lock Lock Lock
     Growth % Lock Lock Lock Lock -77.4 -13.1 -37.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -12 -13 -18 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -3 -4 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -11 -10 -14 Lock Lock Lock
     Growth % Lock Lock Lock Lock -76.7 11.4 -39.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -6 -11 -10 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 31 -1 5 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -6 -11 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -33.2 -70.2 10.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 34 22 17 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 38 27 20 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -34 -22 -17 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 1 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 36 25 18 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 36 25 18 Lock Lock Lock
     Growth % Lock Lock Lock Lock 163.1 -29.4 -28.1 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -29.9 -37.3 -68.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -31.0 -38.9 -75.5 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -46.1 -42.2 -81.4 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -45.0 -32.2 -63.1 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -25.1 -34.6 -43.6 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 3.0 1.7 1.0 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -92.9 -84.4 -93.9 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 24.1 20.4 9.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 24.1 20.4 9.3 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 98.2 91.4 98.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -441.5 -924.8 -511.0 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -29.9 -37.3 -68.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.0 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -31.0 -38.9 -75.5 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -31.0 -38.9 -75.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 743.5 955.5 1,192.4 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -743.5 -955.5 -1,192.4 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.02%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

RAC Shortsell

Frequently Asked Questions

The current share price of Race Oncology Ltd. (RAC:ASX) is AU$1.24.
The 52-week high share price for Race Oncology Ltd. (RAC:ASX) is AU$2.09.
The 52-week low share price for Race Oncology Ltd. (RAC:ASX)? is AU$0.92.
Race Oncology Ltd. (RAC:ASX) does not pay a dividend.
Race Oncology Ltd. (RAC:ASX) does not pay a dividend.
Race Oncology Ltd. (RAC:ASX) has a franking level of 0.0%.
Race Oncology Ltd. (RAC:ASX) is classified in the Healthcare.
The current P/E ratio for Race Oncology Ltd. (RAC:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.